文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer.

作者信息

Govindan Ramaswamy

机构信息

Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA.

出版信息

J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S433. doi: 10.1097/JTO.0b013e3181fd6fe1.

DOI:10.1097/JTO.0b013e3181fd6fe1
PMID:21102234
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3203685/
Abstract
摘要

相似文献

[1]
Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer.

J Thorac Oncol. 2010-12

[2]
A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.

J Thorac Oncol. 2012-12

[3]
Molecular targeted agents and biologic therapies for non-small cell lung cancer.

J Thorac Oncol. 2010-12

[4]
Molecularly targeted therapies in locally advanced non-small-cell lung cancer.

Clin Lung Cancer. 2013-5-14

[5]
[Advances of medical treatment in advanced non-small cell lung cancer in 2011 American Society of Clinical Oncology Annual Meeting].

Zhongguo Fei Ai Za Zhi. 2011-12

[6]
Emerging gene mutation targets in lung cancer.

Clin Adv Hematol Oncol. 2015-12

[7]
[The update of emerging targeted therapies of lung cancer].

Zhonghua Nei Ke Za Zhi. 2017-6-1

[8]
Summary of presentation from the targeted therapy in lung cancer meeting.

J Thorac Oncol. 2011-11

[9]
Targeting MEK for the treatment of non-small-cell lung cancer.

J Thorac Oncol. 2012-12

[10]
Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?

Cancer Biol Ther. 2010-11-1

引用本文的文献

[1]
Comprehensive genomic characterization of squamous cell lung cancers.

Nature. 2012-9-9

[2]
Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer.

J Biomed Biotechnol. 2012

本文引用的文献

[1]
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.

Cancer Res. 2009-7-1

[2]
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Cancer. 2007-8-1

[3]
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

J Clin Oncol. 2006-1-10

[4]
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Lung Cancer. 2006-2

[5]
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Cancer Res. 2005-8-15

[6]
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

Carcinogenesis. 2004-11

[7]
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.

Cancer Res. 2004-1-15

[8]
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Cancer Res. 2002-7-1

[9]
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.

Cancer Res. 2000-11-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索